Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111373 | 0.85 | PPARG (0.42) | PTGDR2PPARGPTGER1 | |
| SCHEMBL5112484 | 0.84 | PPARG (0.54) | PPARGPTGER1 | |
| SCHEMBL5121479 | 0.83 | PPARG (0.49) | PPARDPPARAPTGDR2PPARG | |
| SCHEMBL5114403 | 0.81 | PPARG (0.58) | PPARDPPARAPTGDR2PPARG | |
| SCHEMBL5105449 | 0.80 | PPARG (0.49) | PPARDPPARAPTGDR2PPARG | |
| SCHEMBL5113068 | 0.77 | PPARG (0.39) | PTGDR2PPARGPTGESALOX5 | |
| SCHEMBL5119244 | 0.77 | PPARG (0.52) | PPARGPTGER1 | |
| SCHEMBL28771360 | 0.77 | PPARG (0.47) | PTGDR2PPARGPTGESALOX5 | |
| SCHEMBL3205522 | 0.77 | PTGDR2 (0.47) | PTGDR2PPARGPTGESALOX5 | |
| SCHEMBL5113062 | 0.77 | PPARG (0.52) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARD 189/4885PPARA 118/4885PTGDR2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.